Clinical Trials Browser

Has results × Melanoma × lorukafusp alfa × Clear all

NCT00590824 2019-11-21

Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma

Phase 2 Completed

23 enrolled 22 charts

Melanoma